Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and preliminary antitumor activity data

Presented at the 2023 ASCO Annual Meeting

Hans Gelderblom¹, Mathilde Jalving², Ingrid Desar³, Omar Saavedra Santa Gadea4, Jourik A. Gietema2, Stefan van Ravensteijn³, Nina Ajmone Marsan¹, Anne Bellon5, Sandrine Micallef⁵, Noemie Luong⁵, Luke Piggott⁵, Rikke Frederiksen Franzen⁵, Esteban Rodrigo Imedio⁵

¹Leiden University Medical Center, Leiden, The Netherlands
²University Medical Center Groningen, Groningen, The Netherlands
³Radboud University Medical Centre, Nijmegen, The Netherlands
⁴Vall d’Hebron Institute of Oncology, Barcelona, Spain
⁵Debiopharm International SA, Lausanne, Switzerland

Study objectives

Determine the recommended Phase 2 dose (RP2D) of Debio 0123 when administered in combination with CP and evaluate the safety, tolerability, pharmacokinetics and tumor response.